Chinese Journal of Nephrology, Dialysis & Transplantation ›› 2023, Vol. 32 ›› Issue (1): 95-99.DOI: 10.3969/j.issn.1006-298X.2023.01.020
Previous Articles
Online:
Published:
Abstract: A 42yearold male on regular hemodialysis for one month was referred to our hospital because of weakness and shortness of breath for one day. Laboratory tests showed markedly prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT), which failed to be corrected by APTT mixing test, and thrombin time (TT) was normal. Factor V (FV) activity was decreased and the FV inhibitor was detected. Blood coagulation function returned to normal after glucocorticoid therapy. The patient had a good prognosis and was recurrencefree during one year of followup. Acquired factor V deficiency is a rare coagulopathy with a variety of clinical presentations, and has a poor prognosis in patients with chronic disease. Early diagnosis and treatment can improve the prognosis, and clinicians need to be aware of drugassociated complications.
Key words: uremia, hemodialysis, acquired factor V deficiency, acquired factor V inhibitor, glucocorticoid
GAO Peijuan, HUANG Wenhui, WEI Xiaofang, LI Yingping, HUANG Junyue, LI Xiaoli, ZHAO Hui, ZHANG Jian, DONG Hui, XUE Rong. Acquired factor V deficiency in a hemodialysis patient[J]. Chinese Journal of Nephrology, Dialysis & Transplantation, 2023, 32(1): 95-99.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.njcndt.com/EN/10.3969/j.issn.1006-298X.2023.01.020
http://www.njcndt.com/EN/Y2023/V32/I1/95